Navigation Links
HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
Date:1/4/2012

NEW BRUNSWICK, N.J., Jan. 4, 2012 /PRNewswire/ -- The HealthCare Institute of New Jersey (HINJ) today released key findings of its 2011 economic impact survey, which indicates that the life sciences continue to play a leading role in driving New Jersey's economy. For the eighth consecutive year, the study was conducted by Deloitte.

While the data reported shows a slowing of economic activity, it is important to note that the  2010 results included in the 2011 economic impact survey come from five fewer companies (19) compared to those who contributed the calendar year 2009 results (24), included in the 2010 economic impact survey, making year-to-year comparisons considerably less meaningful. Participation in the annual survey by HINJ member companies is voluntary and confidential.

"Although we had 20 percent fewer companies participating in this year's survey, those that did supply data demonstrate that the life sciences industry continues to be a major economic driver in New Jersey," said Dean J. Paranicas, HINJ's President and Chief Executive Officer. "However, New Jersey continues to face stiff competition from around the world and within the U.S. for our industry's investment. If anything, this data reinforces the need for our leaders in Trenton and Washington to continue to pursue policies that create a more competitive and attractive business climate here, and we look forward to continuing to work with them to achieve this objective."

Paranicas added that HINJ and its member companies applaud actions taken over the past several months by Governor Christie and the State Legislature to make New Jersey more competitive and attractive for life sciences investment. They include an aggressive and competitive business recruitment and retention program, adopting the single sales factor as the basis for calculating New Jersey's corporate business income tax, and enhancing the Business Employment Incentive Program (BEIP) to promote greater private sector collaboration with New Jersey's universities and colleges.

The HINJ findings showed a total economic impact from reporting HINJ member companies of $24.2 billion in calendar year 2010, as compared to $29.3 billion in calendar year 2009. Paranicas explained that this difference reflects fewer companies responding to the survey and may also be accounted for by  the continuing effects of the global recession and industry consolidation.  He also cited reduced capital spending (which is consistent with prevailing economic conditions) and reporting from less than all participants about industry spending with New Jersey-based vendors.

The reported number of full-time employees decreased from 55,366 to 51,619 for the same period, a 6.8 percent decline. Reported capital spending decreased to $0.7 billion in 2010, down from $1.5 billion in 2009, and the economic impact of reported vendor spending was $5.5 billion, down from $8.4 billion in 2009. Gifts to New Jersey non-profit organizations totaled $161 million, down from $214 million in 2009. Total taxes paid in  New Jersey declined to $731 million, from $773 million.

However, Paranicas  also observed that the data submitted by the 16 HINJ member companies that participated in both the 2010 and 2011 surveys shows that the economic impact of those companies was generally constant, at $23.9 billion in 2010 and $24.5 billion in calendar year 2009. Among this cohort, global research and development spending increased by $1.4 billion, to $8.4 billion, and charitable donations in New Jersey also increased 8.1 percent, to $159 million from $147 million.

Paranicas emphasized that there are major bright spots that bode well for future economic activity. Research and development spending in New Jersey was up by 11.4 percent, to $6.1 billion, and medical device trials conducted by reporting companies soared 49.1 percent. Paranicas further noted recent announcements made by HINJ members to expand in New Jersey, as well as by other life sciences companies who have announced they are relocating to, or expanding in, the state.

"We are continuing to see strong life sciences investment in the future and in New Jersey," said Paranicas.

The HealthCare Institute of New Jersey is the trade association for New Jersey's research-based biopharmaceutical and medical device companies. HINJ is providing these key findings from its survey and will release the full results early in 2012. To learn more about HINJ, please visit www.hinj.org.

As used in this document, "Deloitte" means Deloitte LLP and its subsidiaries.  Please see www.deloitte.com/us/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries.  Certain services may not be available to attest clients under the rules and regulations of public accounting.

Contact: Donald Sico
609.351.3591
dsiconj@gmail.com


'/>"/>
SOURCE HealthCare Institute of New Jersey
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
2. Mindray Medical to Attend Morgan Stanley Global Healthcare Unplugged Conference
3. TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm
4. Beckman Coulter to Present at the Thomas Weisel Healthcare Conference 2008
5. Beckman Coulter to Present at the Morgan Stanley Healthcare Unplugged Conference
6. 3SBio Inc. to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
8. Oridion Expands its OEM Partnerships - New Agreement with Spacelabs Healthcare
9. Varian, Inc. to Present at Thomas Weisel Partners 2008 Healthcare Conference
10. Thermage, Inc. to Present at the 2008 Thomas Weisel Partners Healthcare Conference
11. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016  Regular discussions on a range of ... between the two entities said Poloz. Speaking at ... Ottawa , he pointed to the country,s inflation target, ... government. "In certain ... institutions have common economic goals, why not sit down and ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... announce the launch of their brand, UP4™ Probiotics, into Target stores nationwide. The ... is proud to add Target to its list of well-respected retailers. This list ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and Mold) microbial test has received AOAC Research Institute approval 061601. , “This ... introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the ... at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application ... team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our ...
Breaking Biology Technology:
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
(Date:3/23/2016)... 2016 Einzigartige ... und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler Kommunikationsdienste, ... SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie einzusetzen. ... Möglichkeit angeboten, im Rahmen mobiler Apps neben ...
Breaking Biology News(10 mins):